GLP-1 Dosing Safety and How Patients Can Avoid Mistakes
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications prescribed for managing type 2 diabetes and, increasingly, for weight loss. These drugs, which include well-known brands like Ozempic, Mounjaro, Zepbound, and Wegovy, represent a significant advancement in treatment. However, their growing popularity has been accompanied by a sharp rise in dosing errors and safety concerns. Understanding GLP-1 […]
Combined Therapies for T2D Show Improved Cardiac Health
For many years, managing type 2 diabetes (T2D) felt like a single-minded pursuit: get the blood sugar down. While crucial, this approach overlooked a more dangerous threat. People with type 2 diabetes are far more likely to experience serious cardiovascular problems, like heart attacks and strokes. The focus is now shifting towards a more comprehensive […]
Side Effects of Farxiga: What Patients Should Know
Like all medications, Farxiga comes with some possible risk of side effects. Healthcare providers are aware of these potential negative effects and will have taken them into account when issuing a prescription to a specific patient, based on their professional judgment that the benefits that the product gives to their patient outweigh the possible risk. […]
Study shows that early use of tirzepatide for diabetes yields cardiac benefits
Early use of tirzepatide appears to improve blood sugar, weight, and several heart-related risk markers in people with recently diagnosed type 2 diabetes. Interim findings from the SURPASS-EARLY trial conducted by Eli Lilly showed that patients treated within four years of diagnosis achieved stronger glycemic control, greater weight loss, and broader metabolic improvements than those receiving […]
Wegovy pill vs Rybelsus: what’s the difference?
“Wegovy pill” is a term that’s gathering a lot of interest on social media platforms. It refers to a new FDA-approved oral semaglutide tablet doctors can prescribe for weight management. This gets attention because most people are aware of the tremendous changes that the introduction of GLP-1 medications such as Ozempic and Wegovy have made in […]
Diabetes management is the next frontier
Type 2 diabetes (T2D) is one of the most prevalent chronic conditions in the general U.S. population, ranking alongside hypertension (high blood pressure), high cholesterol, and arthritis as one of the four most common chronic diseases. At this point in time, diabetes cannot be completely cured. The four main components of the current approach that […]
Could Tirzepatide be a “Cure” for Type 2 Diabetes?
Normoglycemia is a term that’s drawing a lot of attention in medical circles lately, not because it is new, but because suddenly it seems possible that people who have a medical condition that has always been considered “incurable” may be able to achieve the normal state, which is what normoglycemia is. The thing that’s drawing […]
A Smarter Way to Understand Prediabetes
Both prediabetes and diabetes are very common conditions. Studies have shown that about 38 million adults in the US have been diagnosed as diabetics, which is nearly 15% of the US adult population. Prediabetes is far more common. Reliable estimates put the numbers at just below 100 million adults in the US, although the majority […]
Exercise Is Important for Teens With Type 2 Diabetes
Depression in diabetic teenagers is a real pressure point for many families and clinics. Teens who live with type 2 diabetes carry the daily load of blood sugar checks, food decisions, and health worries. When low mood, sadness, or loss of interest are added on top, life can feel very heavy. New work in physical […]
What to do if GLP-1 Medications Reduce Libido
It’s a difficult question to even ask. Can weight-loss wonder drugs like Ozempic and Wegovy also reduce libido? There’s been a wave of fascination, almost a collective obsession, with this new class of GLP-1 drugs, often described as revolutionary. One topic, however, isn’t being discussed nearly enough. It sits quietly beneath the surface, weighed down […]
